Merck Animal Health Acquires Vence

Merck Animal Health to acquire Elanco's aqua business for ~$1.3B

February 6, 2024

Veterinary

Merck Animal Health has agreed to buy Elanco Animal Health's aqua business for approximately US$1.3 billion in cash. The divestiture — which includes marketed brands, R&D projects, manufacturing sites in Prince Edward Island (Canada) and Dong Nai (Vietnam), and roughly 280 commercial and manufacturing employees — will allow Elanco to focus on higher-growth pet and livestock markets and use proceeds to pay down debt.

Merck & Co., Inc. Acquires VelosBio Inc.

November 5, 2020

Biotechnology

Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.

Elanco Acquires Prevtec Microbia

August 1, 2019

Biotechnology

Elanco Animal Health acquired Montreal-based Prevtec Microbia, maker of the Coliprotec swine E. coli vaccine line, in an all-cash transaction of CAD $78.5 million (approx. $59.9M USD) plus contingent payments of up to CAD $21.5 million. The deal brings Prevtec's commercial vaccines and R&D pipeline into Elanco to expand its swine portfolio and provide non-antibiotic alternatives for swine producers globally.

IMV Technologies Acquires UD-Vet B.V.

September 26, 2024

Veterinary

French animal health equipment maker IMV Technologies has acquired UD-Vet B.V., a Benelux-based provider of veterinary practice equipment and imaging solutions. The deal brings UD-Vet's team and product/service offering into IMV's Companion Animal business to consolidate and expand IMV's presence in the Benelux region.

NovaQuest Capital Management Acquires TechAccel's Stake in Covenant Animal Health Partners

November 30, 2021

Veterinary

NovaQuest Capital Management has acquired TechAccel LLC's ownership stake in Covenant Animal Health Partners, a development and registration partnership focused on revenue-ready animal health products. The move gives NovaQuest full ownership (or increased control) of Covenant to expand its animal health development capabilities and advance new assets into industry partner portfolios.

Sanofi to Acquire Vicebio for Up to $1.6 Billion

July 25, 2025

Biotechnology

Sanofi will acquire clinical-stage biopharmaceutical company Vicebio in a deal worth up to $1.6 billion, including $1.15 billion upfront and $450 million in milestone payments. Vicebio, created by Medicxi using the University of Queensland's Molecular Clamp technology, develops multivalent vaccines targeting respiratory viruses and recently advanced a bivalent RSV/hMPV candidate into Phase 1 trials.